ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
당뇨병성 신경병증 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 2029년에는 CAGR 10.2%로 91억 5,000만 달러로 성장할 것입니다. 예측 기간의 성장은 신경 영상 진단의 발전, 환자 중심 치료 접근법, 임상시험의 확대, 당뇨병 환자의 지속적인 증가, 정밀 의료 접근법, 재생 의학의 확대, 환자 옹호 및 지원 프로그램 등에 기인합니다. 예측 기간의 주요 동향으로는 의학 연구의 공동 연구, 디지털 헬스 솔루션, 진단 기술 발전, 신경 보호 요법, 맞춤형 치료 전략, 인공지능의 통합 등을 꼽을 수 있습니다.
향후 5년간 성장률 10.2%라는 예측은 지난번 예측보다 0.2% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역 마찰로 인해 인도와 이스라엘에서 수입되는 프레가발린과 듀록세틴 제제의 가격이 치솟고, 통증 관리가 제대로 이루어지지 않거나 환자의 자부담이 증가하여 미국의 신경과 의료를 방해할 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.
당뇨병 유병률의 증가가 예상됨에 따라 당뇨병성 신경병증 시장의 큰 폭의 성장이 예상됩니다. 당뇨병은 체내에서 포도당을 적절히 사용하고 저장하지 못하는 것이 특징인 지속적인 질환으로, 당뇨병성 신경병증으로 알려진 다양한 형태의 신경 손상을 유발합니다. 국제당뇨병연맹이 2022년 8월에 발표한 IDF Diabetes Atlas 보고서에서 강조한 바와 같이, 당뇨병으로 인한 전 세계 사망자 수는 2021년에 670만 명에 달할 것으로 예상되며, 이는 5초마다 1명이 사망하는 것과 같습니다. 현재 전 세계 당뇨병 환자 수는 약 5억 3,700만 명, 2030년에는 6억 4,300만 명, 2045년에는 7억 8,300만 명에 달할 것으로 예측됩니다. 이러한 당뇨병 유병률의 증가는 당뇨병성 신경병증 시장의 급격한 성장에 크게 기여하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 당뇨병성 신경병증 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 당뇨병성 신경병증 시장 : 성장률 분석
세계의 당뇨병성 신경병증 시장 실적 : 규모와 성장, 2019-2024
세계의 당뇨병성 신경병증 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 당뇨병성 신경병증 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 당뇨병성 신경병증 시장 : 장애별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
말초신경병증
자율 신경장애
근위 신경장애
국소 신경장애
세계의 당뇨병성 신경병증 시장 : 약물 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
진통제
항우울제
항경련제
기타 약물 클래스
세계의 당뇨병성 신경병증 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
약물 치료
방사선 치료
물리치료
기타 치료법
세계의 당뇨병성 신경병증 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
온라인 유통
오프라인 유통
세계의 당뇨병성 신경병증 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
전문 클리닉
기타 최종사용자
세계의 당뇨병성 신경병증 시장 : 하위 세분화 말초신경병증(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
원위 대칭성 뉴로파치
단신경장애
다발신경장애
세계의 당뇨병성 신경병증 시장 : 하위 세분화 자율 신경장애(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
심혈관 자율 신경장애
소화관 자율 신경장애
비뇨생식기 자율 신경 장애
세계의 당뇨병성 신경병증 시장 : 하위 세분화 근위 신경장애(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
당뇨병성 근위축증
요선부 신경총 신경장애
세계의 당뇨병성 신경병증 시장 : 하위 세분화 국소성 신경장애(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
뇌신경 장애
경추 신경근증
기타 국소 신경장애
제7장 지역별·국가별 분석
세계의 당뇨병성 신경병증 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 당뇨병성 신경병증 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
당뇨병성 신경병증 시장 : 경쟁 구도
당뇨병성 신경병증 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
Daiichi Sankyo Company Limited Overview, Products and Services, Strategy and Financial Analysis
Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
Depomed Inc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
F. Hoffmann-La Roche AG
NeuroMetrix Inc
Lupin Limited
Novartis AG
Boehringer Ingelheim
Regenacy Pharmaceuticals Inc.
Merck & Co. Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Merck KGaA
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
당뇨병성 신경병증 시장 2029 : 새로운 기회를 제공하는 국가
당뇨병성 신경병증 시장 2029 : 새로운 기회를 제공하는 부문
당뇨병성 신경병증 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
KSM
영문 목차
영문목차
Diabetic neuropathy is a form of nerve damage that can affect individuals with diabetes, often resulting from elevated blood sugar levels that cause damage to blood vessels. This condition can impact various nerves in the body, including those in the feet, organs, and muscles.
The primary types of diabetic neuropathy include peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. Peripheral neuropathy occurs when the peripheral nerves, responsible for transmitting information between the brain, spinal cord, and the rest of the body, are damaged. Treatment for diabetic neuropathy involves various classes of drugs, such as analgesics, anti-depressants, anti-convulsant, and others, along with approaches such as drug treatment, radiotherapy, physiotherapy, and more. These treatments are made available through different distribution channels, including online and offline channels, and are utilized in settings such as hospitals, specialty clinics, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The diabetic neuropathy market research report is one of a series of new reports from The Business Research Company that provides diabetic neuropathy market statistics, including diabetic neuropathy industry global market size, regional shares, competitors with a diabetic neuropathy market share, detailed diabetic neuropathy market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic neuropathy industry. This diabetic neuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The diabetic neuropathy market size has grown strongly in recent years. It will grow from $5.79 billion in 2024 to $6.21 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to rising global diabetes prevalence, increased awareness and diagnosis, advancements in diabetic care, growing healthcare expenditure, research and development investments, patient education initiatives.
The diabetic neuropathy market size is expected to see rapid growth in the next few years. It will grow to $9.15 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to advancements in neuroimaging, patient-centric care approaches, expansion of clinical trials, continued rise in diabetes cases, precision medicine approaches, expansion of regenerative medicine, patient advocacy and support programs. Major trends in the forecast period include collaborative efforts in medical research, digital health solutions, advancements in diagnostic technologies, neuroprotective therapies, personalized treatment strategies, integration of artificial intelligence.
The forecast of 10.2% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. neurology care by inflating prices of pregabalin and duloxetine formulations imported from India and Israel, resulting in inadequate pain management and higher patient out-of-pocket costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The projected increase in diabetes prevalence is anticipated to drive substantial growth within the diabetic neuropathy market. Diabetes, a persistent condition characterized by the body's inability to adequately use and store glucose, leads to various forms of nerve damage known as diabetic neuropathy. As highlighted in the IDF Diabetes Atlas report released by the International Diabetes Federation in August 2022, the global toll from diabetes-related deaths amounted to 6.7 million in 2021, equating to one fatality every five seconds. Presently, there are approximately 537 million adults (aged 20-79) living with diabetes worldwide, a figure predicted to surge to 643 million by 2030 and 783 million by 2045. This escalating diabetes prevalence significantly contributes to the burgeoning diabetic neuropathy market.
The expanding proportion of the elderly population is poised to fuel the growth of the diabetic neuropathy market. As individuals age, the likelihood of developing diabetes and associated complications, including neuropathy, increases. Diabetic neuropathy encompasses nerve damage common in diabetic individuals, leading to symptoms such as numbness, tingling, and pain in affected areas. As per projections by the World Health Organization in October 2022, by 2030, one out of every six individuals globally will be aged 60 years or older, with the population of those aged 60 years and above set to surge from 1 billion in 2020 to 1.4 billion. By 2050, the worldwide population of individuals aged 60 years and older is expected to double, reaching 2.1 billion, with the number of individuals aged 80 years or older tripling to 426 million. This aging demographic is expected to drive demand for diabetic neuropathy treatments.
Major companies in the diabetic neuropathy market are developing advanced products, such as neuromodulation therapy devices, to improve treatment options for patients experiencing chronic pain linked to diabetic neuropathy. These devices provide non-invasive treatment by modulating nerve activity to alleviate pain, enhance nerve function, and promote healing in individuals with diabetic nerve damage. For example, in January 2024, Neuralace Medical, Inc., a US-based company specializing in non-drug pain management treatments, received approval from the Food and Drug Administration (FDA) for its Axon Therapy designed for Chronic Painful Diabetic Neuropathy (CPDN). This innovative device employs neuromodulation techniques to relieve pain associated with diabetic neuropathy, representing a significant advancement in pain management options for affected patients. The FDA clearance highlights the device's safety and efficacy, enabling Neuralace to proceed with commercialization and broaden access to effective treatment solutions for those suffering from CPDN.
Prominent companies within the diabetic neuropathy market are actively pursuing strategic partnerships and alliances to foster innovation and fortify their market positions. These alliances, formal agreements between multiple businesses, aim to leverage shared resources, knowledge, or expertise to achieve mutual objectives. For instance, in July 2022, Teva Pharmaceutical Industries Ltd., an Israel-based clinical-stage biopharmaceutical company, joined forces with NeuroFront Therapeutics Limited, a Hong Kong-based biotech firm, in an exclusive alliance and commercialization pact for Novaremed's pioneering non-opioid investigational drug, NRD.E1. This drug is specifically designed to treat diabetes-associated neuropathic pain and other related indications. This strategic collaboration enables the development and commercialization of an innovative therapy for neuropathic pain management.
In January 2022, Withings SA, a France-based consumer electronics company specializing in clinically validated smart health devices and associated apps, completed the acquisition of Impeto Medical SAS for an undisclosed sum. This strategic acquisition empowers Withings to integrate Impeto's cutting-edge technologies, including nerve tracking activity, into its product portfolio and services. Impeto Medical SAS, a France-based medical device company, manufactures tools for monitoring peripheral neuropathies to detect small fiber neuropathies in various diseases and conditions. This acquisition strengthens Withings' capabilities by incorporating advanced nerve tracking technologies, enhancing their offerings for neuropathy monitoring and management within their health devices and services lineup.
Major companies operating in the diabetic neuropathy market include Pfizer Inc., Eli Lilly and Company, Daiichi Sankyo Company Limited, Johnson & Johnson, Depomed Inc., F. Hoffmann-La Roche AG, NeuroMetrix Inc, Lupin Limited, Novartis AG, Boehringer Ingelheim, Regenacy Pharmaceuticals Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Merck KGaA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Zydus Cadila, Biogen Inc., Genentech Inc.
North America was the largest region in the diabetic neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the diabetic neuropathy market during the forecast period. The regions covered in the diabetic neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the diabetic neuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The diabetic neuropathy market consists of sales of drugs such as anticonvulsants, pain medications, nerve growth factor inhibitors and other drugs that are used to treat the symptoms of nerve damage caused by diabetes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Diabetic Neuropathy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on diabetic neuropathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for diabetic neuropathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diabetic neuropathy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Diabetic Neuropathy Market Characteristics
3. Diabetic Neuropathy Market Trends And Strategies
4. Diabetic Neuropathy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Diabetic Neuropathy Growth Analysis And Strategic Analysis Framework
5.1. Global Diabetic Neuropathy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Diabetic Neuropathy Market Growth Rate Analysis
5.4. Global Diabetic Neuropathy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Diabetic Neuropathy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Diabetic Neuropathy Total Addressable Market (TAM)
6. Diabetic Neuropathy Market Segmentation
6.1. Global Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Peripheral Neuropathy
Autonomic Neuropathy
Proximal Neuropathy
Focal Neuropathy
6.2. Global Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Analgesics
Anti-Depressants
Anti-consulvants
Other Drug Classes
6.3. Global Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Drug Treatment
Radiotherapy
Physiotherapy
Other Treatments
6.4. Global Diabetic Neuropathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Online Distribution
Offline Distribution
6.5. Global Diabetic Neuropathy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Other End-users
6.6. Global Diabetic Neuropathy Market, Sub-Segmentation Of Peripheral Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Distal Symmetric Neuropathy
Mononeuropathy
Polyneuropathy
6.7. Global Diabetic Neuropathy Market, Sub-Segmentation Of Autonomic Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cardiovascular Autonomic Neuropathy
Gastrointestinal Autonomic Neuropathy
Genitourinary Autonomic Neuropathy
6.8. Global Diabetic Neuropathy Market, Sub-Segmentation Of Proximal Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diabetic Amyotrophy
Lumbosacral Plexus Neuropathy
6.9. Global Diabetic Neuropathy Market, Sub-Segmentation Of Focal Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cranial Neuropathy
Cervical Radiculopathy
Other Focal Neuropathies
7. Diabetic Neuropathy Market Regional And Country Analysis
7.1. Global Diabetic Neuropathy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Diabetic Neuropathy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
